FNCHQ (Finch Therapeutics Group) Marketable Securities: $0.00 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FNCHQ Finch Therapeutics Group Inc FNCHQ
12 GF Score
Price $10.20
View Full Analysis

What is Finch Therapeutics Group Marketable Securities?

Finch Therapeutics Group FNCHQ 12 Marketable Securities is $0.00 Mil as of Jun. 2024. GuruFocus rates FNCHQ with a GF Score™ of 12/100.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Finch Therapeutics Group's Marketable Securities for the quarter that ended in Jun. 2024 was $0.00 Mil.

Finch Therapeutics Group  (OTCPK:FNCHQ) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Finch Therapeutics Group Marketable Securities Related Terms

Finch Therapeutics Group Marketable Securities Historical Data

* Premium members only.

The historical data trend for Finch Therapeutics Group's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Finch Therapeutics Group Marketable Securities Chart

Finch Therapeutics Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Marketable Securities
0.00 0.00 0.00 0.00 0.00

Finch Therapeutics Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FNCHQ
12GF Score
Finch Therapeutics Group Inc FNCHQ
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Finch Therapeutics Group Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Finch Therapeutics Group (FNCHQ) has a Marketable Securities of $0.00 Mil as of Jun. 2024. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Finch Therapeutics Group and its competitors.
Is Finch Therapeutics Group's Marketable Securities too high?
Finch Therapeutics Group's current Marketable Securities is $0.00 Mil. Overall, Finch Therapeutics Group has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Finch Therapeutics Group's Marketable Securities compare to CRIS and LSB?
Finch Therapeutics Group's Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Finch Therapeutics Group and its competitors. Finch Therapeutics Group's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Finch Therapeutics Group stock overvalued right now?
Finch Therapeutics Group (FNCHQ) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. Finch Therapeutics Group's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Finch Therapeutics Group (FNCHQ), the current Marketable Securities is $0.00 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Finch Therapeutics Group Business Description

Address 75 State Street, Suite 100, Boston, MA, USA, 02109
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
12GF Score

Get the complete analysis for FNCHQ

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.20
Price